Tumor Multiplicity Is an Independent Prognostic Factor of Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy

REFERENCES

• Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2001;51:15–36.
   PubMed Web of Science ®Google Scholar
• Sellami A, Jlidi R, Hsaıri M, Achour N. Registre du cancer du sud Tunisie 1997. Hôpital Habib Bourguiba. 2000;2:32–35.
   Google Scholar
• Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF. Superficial bladder cancer treated with Bacillus Calmette–Guérin: a multivariate analysis of factors affecting tumor progression. J Urol. 1989;141: 22–29.
   PubMed Web of Science ®Google Scholar
• Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical BCG therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13:1404–1408.
   PubMed Web of Science ®Google Scholar
• Saint F, Salomon L, Quintela R. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol. 2003;43:351–361.
   PubMed Web of Science ®Google Scholar
• Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001; 166:1296–1299.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49: 466–477.
   PubMed Web of Science ®Google Scholar
• Takashi M, Wakai K, Hattori T, et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol. 2002;33:41–47.
   PubMedGoogle Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73–78.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435–1448.
   PubMed Web of Science ®Google Scholar
• Sobin DH, Wittekind CH, eds. TNM Classification of Malignant Tumours, 6th ed. New York: Wiley-Liss; 2002: 199–202.
   Google Scholar
• Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette–Guérin of existing papillary bladder cancer and carcinoma in situ of the bladder: four-year results. Cancer. 1995;75:552–559.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical Bacillus Calmette–Guerin therapy. J Urol. 1992;148:797–801.
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro JA, Flores N, Isorna S, et al. Long-term follow-up of randomised prospective trial comparing a standard 81 mg dose of intravesical Bacillus Calmette–Guérin with reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89:671–680.
   PubMed Web of Science ®Google Scholar
• Zlotta RA, Noel JC, Fayt I, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki67 expression in patients with superficial bladder tumors treated with Bacillus Calmette–Guérin intravesical therapy. J Urol. 1999;161:792–798.
   PubMed Web of Science ®Google Scholar
• Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with Bacillus Calmette–Guerin: progression-free and disease specific survival with 10-year minimum followup. J Urol. 2002;167:494–501.
   PubMed Web of Science ®Google Scholar
• Kondylis FI, Demirci S, Ladaga L, Kolm P, Schellhammer PF. Outcomes after intravesical Bacillus Calmette–Guérin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol. 2000; 163:1120–1123.
   PubMed Web of Science ®Google Scholar
• van der Meijden AP, Sylvester RJ. BCG immunotherapy for superficial bladder cancer: an overview of the past, the present and the future. EAU Update Series. 2003;1:80–86
   Google Scholar
• Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette–Guérin: 18-year experience. Urology. 2002; 59:227–231.
   PubMed Web of Science ®Google Scholar
• Lebret T, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose Bacillus Calmette–Guérin instillations. J Urol. 2000;163:63–67.
   PubMed Web of Science ®Google Scholar
• Yuge K, Kikuchi E, Matsumoto K, Takeda T, Miyajima A, Oya M. Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy? Jpn J Clin Oncol 2011;41(4):565–570.
   PubMed Web of Science ®Google Scholar
• Saint F, Salomon L, Quintela R. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol. 2003;43:351–361.
   PubMed Web of Science ®Google Scholar
• Takashi M, Wakai K, Hattori T, et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol. 2002;33:41–47.
   PubMedGoogle Scholar
• Martinez-Pineiro JA, Flores N, Isorna S, et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacilli Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89:671–680.
   PubMed Web of Science ®Google Scholar
• Shinka T, Matsumoto M, Ogura H, Hirano A, Ohkawa T. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up. Int J Urol. 1997;4:139–143.
   PubMedGoogle Scholar
• Joudi FN, Smith BJ, O’Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175:1634–1639.
   PubMed Web of Science ®Google Scholar
• Cho KS, Hwang TK, Kim BW, et al, for the Korean Urological Oncology Society. Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age. Urology. 2009:73:828–832.
   PubMed Web of Science ®Google Scholar
• Losa A, Hurle R, Lembo A. Low dose Bacillus Calmette–Guérin for carcinoma in situ of the bladder: long-term results. J Urol. 2000; 163:68–72.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int. 2010;106(3):357–361.
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non–muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53: 992–1002.
   PubMed Web of Science ®Google Scholar